JCO:曲妥珠单抗、帕妥珠单抗和多西他赛联合用于伴有HER2突变的晚期非小细胞肺癌患者
<section style="color: rgb(0, 0, 0); font-variant-numeric: normal; font-variant-east-asian: normal; margin: 0px; padding: 0px 0.5em; outline: 0px; max-width: 100%; font-family: -apple-system, BlinkMacSystemFont, " helvetica="" neue",="" "pingfang="" sc",="" "hiragino="" sans="" gb",="" "microsoft="" yahei="" ui",="" yahei",="" arial,="" sans-serif;="" letter-spacing:="" 0.544px;="" widows:="" 1;="" font-size:="" medium;="" line-height:="" 1.75em;="" box-sizing:="" border-box="" !important;="" overflow-wrap:="" break-word="" !important;"="">
https://ascopubs.org/doi/full/10.1200/JCO.21.01455
copyright©金宝搏网站登录技巧 版权所有,未经许可不得复制、转载或镜像
京ICP证120392号 京公网安备110105007198 京ICP备10215607号-1 (京)网药械信息备字(2022)第00160号